Docoh
Loading...

DVAX Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Company profile

Ticker
DVAX
Exchange
CEO
Ryan Spencer
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
330728374

DVAX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

25 Feb 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 32.31M 32.31M 32.31M 32.31M 32.31M 32.31M
Cash burn (monthly) 201.33K 649.17K 3.97M 5.7M 5.25M 7.69M
Cash used (since last report) 728.68K 2.35M 14.35M 20.62M 18.99M 27.82M
Cash remaining 31.58M 29.96M 17.96M 11.69M 13.32M 4.49M
Runway (months of cash) 156.9 46.2 4.5 2.1 2.5 0.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Apr 21 David F Novack Common Stock Sell Dispose S No Yes 9.92 20,000 198.4K 117,399
12 Mar 21 Janssen Robert Common Stock Gift Dispose G No No 0 1,000 0 86,861
2 Mar 21 Justin Burgess Common Stock Sell Dispose S No No 8.82 1,165 10.28K 7,010
1 Mar 21 Kelly MacDonald Stock Option Common Stock Grant Aquire A No No 8.9 350,000 3.12M 350,000
1 Mar 21 Justin Burgess Common Stock Sell Dispose S No No 8.88 1,633 14.5K 8,175
1 Mar 21 Justin Burgess Common Stock Sell Dispose S No No 8.88 1,325 11.77K 9,808
1 Mar 21 Justin Burgess Common Stock Option exercise Aquire M No No 0 2,839 0 11,133
1 Mar 21 Justin Burgess RSU Common Stock Option exercise Dispose M No No 0 2,839 0 0
26 Feb 21 Justin Burgess Common Stock Option exercise Aquire M No No 0 3,906 0 8,294
26 Feb 21 Justin Burgess Common Stock Option exercise Aquire M No No 0 3,167 0 4,388

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

64.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 142 165 -13.9%
Opened positions 11 42 -73.8%
Closed positions 34 28 +21.4%
Increased positions 53 49 +8.2%
Reduced positions 43 40 +7.5%
13F shares
Current Prev Q Change
Total value 467.07M 877.07M -46.7%
Total shares 73.21M 88.16M -17.0%
Total puts 762.2K 842.2K -9.5%
Total calls 568.3K 797.4K -28.7%
Total put/call ratio 1.3 1.1 +27.0%
Largest owners
Shares Value Change
FHI Federated Hermes 11.95M $53.16M +9.1%
STT State Street 10.89M $48.45M -6.2%
BLK Blackrock 8.19M $36.44M +0.3%
Chicago Capital 5.78M $25.73M +47.1%
Vanguard 5.11M $22.75M -1.8%
Avidity Partners Management 4M $17.8M +97.5%
Partner Fund Management 2.94M $13.07M 0.0%
Blair William & Co 2.18M $9.72M +7.2%
GS Goldman Sachs 2.03M $9.06M +168.4%
Rock Springs Capital Management 1.65M $7.34M +0.1%
Largest transactions
Shares Bought/sold Change
Bain Capital Life Sciences Investors 0 -10.9M EXIT
Citadel Advisors 69.63K -2.03M -96.7%
Avidity Partners Management 4M +1.98M +97.5%
Chicago Capital 5.78M +1.85M +47.1%
Redmile 1.22M -1.33M -52.3%
GS Goldman Sachs 2.03M +1.28M +168.4%
Millennium Management 104.16K -1.01M -90.7%
FHI Federated Hermes 11.95M +1M +9.1%
Two Sigma Investments 425.69K -872.02K -67.2%
AMP Ameriprise Financial 1.32M -788.57K -37.5%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accuracy, acellular, alter, anesthesiologist, Assent, bargaining, Biden, BMGF, bond, booster, Brexit, bridge, broader, cancellation, capture, CEO, CEPI, cGMP, charitable, CHMP, Coalition, commerce, compliant, composition, compound, constitutionality, coupled, COVID, CPRA, creative, cutoff, cybersecurity, dedicate, differentially, diphtheria, disproportionate, distancing, drastically, driver, EEA, eighty, elderly, exacerbated, expiry, explained, exploit, factor, felt, fine, flu, forensic, forgivable, forgiven, Foundation, fundamental, GASC, gradually, half, harbor, harder, headwind, highlighted, Importantly, influenza, inJanuary, intensified, inter, Internationally, invoice, invoked, IPR, Israel, JUSTIN, Kingdom, labor, lawfully, leadership, length, lifted, Medicinal, Melinda, mix, Moderna, nationwide, nondiscriminatory, nurse, offsite, online, onsite, outpace, output, paradiso, paused, peter, PGR, pharmacy, philanthropic, phishing, phone, polarized, pose, posed, pre, predecessor, preferential, premier, promptly, proportion, proportional, punitive, question, reactogenicity, recession, reconsider, reliant, remote, remotely, reorder, repay, replenished, restoration, revealed, robust, Royal, scam, science, Scotland, sequester, seroprotection, shelter, Shield, shift, shifting, shipment, stall, stiff, strict, Supreme, Surefire, surety, survey, Switzerland, talent, Tdap, tender, tenure, tie, uninterrupted, unknown, unnecessary, unredacted, unrelated, unsecured, unusual, viable, video, virtual, visit, wholly, worsening
Removed: accommodate, allocable, arnold, attestation, autoimmune, bearing, broadening, charter, complaint, complying, david, declare, deployed, directed, Double, eliminating, generic, Helix, immunotherapy, implied, inflammatory, interference, invent, investigational, licensee, listed, lowering, MAA, necessarily, nominating, oncology, oronsky, outplacement, paragraph, pipeline, posted, PPACA, preceding, premium, print, PTO, retrospective, Trademark, Unaudited, writing

Patents

GRANT
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
24 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
GRANT
Utility
Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
27 Jul 20
The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker.
APP
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
24 Jun 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
13 Apr 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Branched chimeric compounds, and methods of use thereof
3 Feb 20
The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides.